Clinical Trial Update: Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. [Phase 1]

View source ↗

Summary

Phase 1 study of pembrolizumab plus vorinostat in relapsed or refractory B-cell lymphomas and classic Hodgkin lymphoma; results posted in February 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma Unclassifiable with Features Intermediate Between Dlbcl and Classic Hodgkin Lymphoma
• Classic Hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mediastinal Large B-cell Lymphoma
• Non-hodgkin Lymphoma
• Transformed Non-hodgkin Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Zolinza (vorinostat)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-02-01